Skip to main content
. 2023 Jan 24;8(2):e164767. doi: 10.1172/jci.insight.164767

Figure 4. Dose intensity of cyclophosphamide, doxorubicin, rituximab, and vincristine according to sex and the time of the day of R-CHOP delivery.

Figure 4

(A) The definition of dose intensity (DI), planned dose intensity (PDI), and relative dose intensity (RDI). (B–E) RDI of cyclophosphamide (B), doxorubicin (C), rituximab (D), and vincristine (E) in MG and AG, female MG and AG, and male MG and AG. (F–I) The fraction of patients receiving less than 80% of PDI of cyclophosphamide (F), doxorubicin (G), rituximab (H), and vincristine (I) in MG and AG, female MG and AG, and male MG and AG. Here, 129 patients in the adverse event cohort were analyzed. P values in B–E and those in F–I were calculated by Mann-Whitney U test and χ2 test, respectively. Error bar denotes IQR. *P < 0.05; **P < 0.01.